Clinical Trials Logo

Healthy Volunteers clinical trials

View clinical trials related to Healthy Volunteers.

Filter by:

NCT ID: NCT02616835 Completed - Healthy Volunteers Clinical Trials

Investigating the Physiology of Targeted Theta-burst Neuromodulation

Start date: August 2014
Phase: N/A
Study type: Interventional

This research seeks to study the physiological effects of theta-burst transcranial magnetic stimulation (TMS) in the brains of healthy controls using functional MRI and spectroscopy.

NCT ID: NCT02616445 Completed - Healthy Volunteers Clinical Trials

Phase I MAD, Fed-Fasted, CSF Study of UE2343 in Healthy Subjects

Start date: February 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether the drug UE2343, a potential treatment for Alzheimer's Disease (AD), is effective by assessing safety, tolerability, pharmacokinetics and pharmacodynamics in a Multiple Ascending Dose Study. Protocol amendments to the study will examine any food effect and determine if the drug penetrates the Blood-Brain Barrier.

NCT ID: NCT02615951 Completed - Healthy Volunteers Clinical Trials

Characterization of Breg Cells

Breg
Start date: October 2, 2015
Phase: N/A
Study type: Interventional

Recently, it has been shown that B cells could also have regulatory functions through the secretion of interleukin 10 (IL-10). They are called the B regulatory cells (Breg). In the mouse model the most commonly used of rheumatoid arthritis, collagen-induced arthritis (CIA), the transfer Breg helps prevent the development of CIA and cure established arthritis. The investigators have recently shown that Breg were decreased in patients with RA compared to controls and that the rate of Breg was inversely correlated with disease activity and autoantibody. These results thus suggest that the lack of IL-10 secretion by B cells plays an important role in the pathophysiology of RA. Nevertheless, in humans, the Breg remain poorly understood. The main objective of this project is to better characterize the B capable of producing IL-10 both in subjects with RA and controls. Understanding which induces the secretion of IL-10 by B could allow to consider new therapeutic approaches in autoimmune diseases, including in RA. The investigators therefore aim to identify nutrient transporters, chemokine receptors, genes and surface proteins differentially expressed between Breg and other B cells in patients with RA and in controls.

NCT ID: NCT02614755 Completed - Healthy Volunteers Clinical Trials

An Observational Study of Lumosity in Seniors

Start date: November 2015
Phase: N/A
Study type: Observational

The primary objective of this observational study is to determine performance characteristics and usability of Lumosity and the Brain Performance Test in a group of older adult volunteers.

NCT ID: NCT02610647 Completed - Healthy Volunteers Clinical Trials

Functional Significance of Complexity Measures in the Sensory-motor Behavior

NEURO COMP
Start date: June 6, 2017
Phase: N/A
Study type: Interventional

The main objective of this study is to compare between groups the level of complexity of the estimated sensorimotor performance through multi-fractal (minmaxMF-DFA) exponents.

NCT ID: NCT02606682 Completed - Healthy Volunteers Clinical Trials

Phase 1 Study of NPT200-11 in Healthy Subjects

Start date: July 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability and blood levels of orally administered NPT200-11 in healthy subjects. In addition, the maximally tolerated dose will be determined.

NCT ID: NCT02603224 Completed - Healthy Volunteers Clinical Trials

Safety, Tolerability and Pharmacokinetic Study of MRG-201 in Healthy Volunteers

Start date: November 2015
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety and tolerability of the investigational drug, MRG-201, in healthy volunteers. MRG-201 is designed to mimic the activity of a molecule called miR-29 that decreases the expression of collagen and other proteins that are involved in scar formation. MRG-201 is being studied to determine if it can limit the formation of fibrous scar tissue in certain diseases. MRG-201 will be tested in healthy volunteers by injection into intact skin or adjacent to a short skin incision. Volunteers may receive one or several doses of MRG-201, and will be monitored for local reactions in the skin, signs or symptoms of adverse effects on the body, and for the levels of MRG-201 in the blood over time. Skin biopsies will also be collected to study how cells in the skin respond when exposed to MRG-201.

NCT ID: NCT02602860 Completed - Healthy Volunteers Clinical Trials

A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers

Start date: November 2015
Phase: Phase 1
Study type: Interventional

This study will estimate how fast two antiepileptic drugs (Levetiracetam and Brivaracetam) enter the human brain. Brain imaging will be used to measure how quickly the radioactive probe [11C]UCB-J exits the brain when Levetiracetam or Brivaracetam are given. This will be used to estimate how fast the antiepileptic drugs enter the brain.

NCT ID: NCT02601001 Completed - Healthy Volunteer Clinical Trials

Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults

Start date: November 13, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of omecamtiv mecarbil in healthy volunteers in Japan.

NCT ID: NCT02596789 Completed - Healthy Volunteers Clinical Trials

Cortical Excitability Using Transcranial Magnetic Stimulation and Neuronavigation Device

RC-TMS
Start date: June 2012
Phase: N/A
Study type: Interventional

This study has two main goals : - to investigate the impact of aging on cortical excitability (CE) - to investigate the impact of "state dependency" on CE, using a cognitive task and an emotional one. A Neuronavigation system of transcranial magnetic stimulation is used, and electromyographic response are recorded.